Shattuck Labs, Inc. (NASDAQ:STTK) Director Acquires $166,713.75 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK) Director Redmile Group, Llc acquired 133,371 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were bought at an average price of $1.25 per share, for a total transaction of $166,713.75. Following the acquisition, the director now owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This represents a 2.47 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shattuck Labs Trading Down 4.6 %

Shattuck Labs stock opened at $1.25 on Monday. Shattuck Labs, Inc. has a 12 month low of $0.94 and a 12 month high of $11.76. The stock’s 50 day simple moving average is $1.30 and its two-hundred day simple moving average is $3.34. The firm has a market cap of $59.68 million, a PE ratio of -0.82 and a beta of 1.76.

Institutional Investors Weigh In On Shattuck Labs

Several hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its position in shares of Shattuck Labs by 209.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock valued at $857,000 after buying an additional 150,340 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Shattuck Labs by 38.2% during the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after buying an additional 502,860 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Shattuck Labs during the 3rd quarter valued at approximately $121,000. American Century Companies Inc. lifted its position in shares of Shattuck Labs by 25.4% during the 2nd quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock valued at $183,000 after buying an additional 9,608 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of Shattuck Labs during the 2nd quarter valued at approximately $170,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on STTK. Evercore ISI upgraded shares of Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a report on Thursday, November 14th. Citigroup downgraded shares of Shattuck Labs from a “buy” rating to a “neutral” rating and cut their price target for the stock from $8.00 to $2.00 in a report on Wednesday, October 2nd. Finally, HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Shattuck Labs presently has a consensus rating of “Hold” and an average price target of $8.67.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.